A Double-blind, Randomized, Placebo-controlled, Two-centre, Phase IIa Pharmacodynamic Cross-over Study to Assess the Effect of AZD2516 on the Total Number of Reflux Episodes in Healthy Male Volunteers.
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2012
At a glance
- Drugs AZD 2516 (Primary)
- Indications Gastro-oesophageal reflux; Neuropathic pain
- Focus Pharmacodynamics
- 05 Jul 2012 Actual patient number changed from 25 to 20 as reported by ClinicalTrials.gov.
- 06 Dec 2010 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
- 26 Nov 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.